Home › Companies › Agios Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Agios Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2026: 6 items on Agios Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 3 approved · 3 passed (calculated).
Significant dissent: 1 director (31.7% against).
Notable dissent: 1 director (12.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Agios Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Agios Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Rahul Ballal, Ph.D. | 40,145,081 | -- | -- | 5,943,999 | 2,554,446 | 87% | Passed (calculated) | — |
| Elect Director: Brian Goff | 45,757,238 | -- | -- | 331,843 | 2,554,446 | 99.3% | Passed (calculated) | — |
| Elect Director: Cynthia Smith | 31,496,376 | -- | -- | 14,592,704 | 2,554,446 | 68% | Passed (calculated) | — |
| 2. Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. | 43,396,045 | 1,086,059 | 1,606,976 | -- | 2,554,446 | 98% | Approved | — |
| 3. Company's stockholders approved the 2023 Plan Amendment. | 43,549,751 | 2,527,678 | 11,651 | -- | 2,554,446 | 95% | Approved | — |
| 4. Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | 48,511,213 | 116,938 | 15,376 | -- | 0 | 99.8% | Approved | — |
Source: Agios Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
253 asset managers disclosed a vote on at least one Agios Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Brian Goff
Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian Goff”): 45,757,238 for, 331,843 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,612,263 | 0 | 1 | 0 | For |
| BlackRock | 2,942,277 | 0 | 0 | 0 | For |
| State Street | 2,202,586 | 0 | 0 | 23 | For |
| Fidelity | 1,606,123 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,158,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 858,121 | 0 | 0 | 0 | For |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 272,612 | 0 | 0 | 0 | For |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 124,191 | 0 | 0 | 0 | For |
| American Century | 121,737 | 0 | 0 | 0 | For |
| Invesco | 111,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 91,876 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 83,229 | 0 | 0 | 0 | For |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,487 | 0 | 0 | 0 | For |
| Northwestern Mutual | 38,434 | 0 | 0 | 0 | For |
| Brighthouse | 35,420 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 17,783,176 for, 8,657 withheld, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,704,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,704,900 for.
Combines 5 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith
Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Cynthia Smith”): 31,496,376 for, 14,592,704 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,612,215 | 0 | 49 | 0 | For |
| BlackRock | 0 | 0 | 0 | 2,942,277 | Withhold |
| State Street | 15,642 | 0 | 0 | 2,186,967 | Withhold |
| Fidelity | 1,575,310 | 0 | 0 | 30,813 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 1,158,514 | Withhold |
| T. Rowe Price | 208,574 | 0 | 0 | 649,547 | Mixed |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 272,612 | 0 | 0 | 0 | For |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 3,491 | 0 | 0 | 120,700 | Withhold |
| American Century | 121,737 | 0 | 0 | 0 | For |
| Invesco | 111,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 91,876 | Withhold |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 83,229 | Withhold |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,787 | 0 | 0 | 38,700 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 38,434 | Withhold |
| Brighthouse | 19,125 | 0 | 0 | 16,295 | Mixed |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 10,265,833 for, 7,525,953 withheld, 49 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,704,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,704,900 for.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D.
Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Rahul Ballal, Ph.D.”): 40,145,081 for, 5,943,999 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,612,245 | 0 | 19 | 0 | For |
| BlackRock | 2,942,277 | 0 | 0 | 0 | For |
| State Street | 15,731 | 0 | 0 | 2,186,878 | Withhold |
| Fidelity | 1,606,123 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,158,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 208,574 | 0 | 0 | 649,547 | Mixed |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 272,612 | 0 | 0 | 0 | For |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 84,451 | 0 | 0 | 39,740 | Mixed |
| American Century | 121,737 | 0 | 0 | 0 | For |
| Invesco | 111,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 91,876 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 83,229 | 0 | 0 | 0 | For |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,787 | 0 | 0 | 38,700 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 38,434 | Withhold |
| Brighthouse | 35,420 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 14,789,168 for, 3,002,648 withheld, 19 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,704,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,704,900 for.
95% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,000,000 SHARES.
Agios Pharmaceuticals, Inc.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 43,549,751 for, 2,527,678 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the 2023 Plan Amendment.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 17,032,412 for, 757,478 against, 3,915 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,606,787 | 5,476 | 0 | 0 | For |
| BlackRock | 2,942,277 | 0 | 0 | 0 | For |
| State Street | 2,199,683 | 2,926 | 0 | 0 | For |
| Fidelity | 1,301,585 | 304,538 | 0 | 0 | Mixed |
| Delaware/Macquarie | 1,158,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 858,121 | 0 | 0 | 0 | For |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 0 | 272,612 | 0 | 0 | Against |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 124,191 | 0 | 0 | 0 | For |
| American Century | 0 | 121,737 | 0 | 0 | Against |
| Invesco | 111,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 91,876 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 83,229 | 0 | 0 | 0 | For |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,487 | 0 | 0 | 0 | For |
| Northwestern Mutual | 38,434 | 0 | 0 | 0 | For |
| Brighthouse | 35,420 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 93.9% for (June 18, 2025 meeting) ▲ 3.6 pts
Description as filed by funds: To vote, on an advisory basis, to approve the compensation paid to our named executive officers.
Agios Pharmaceuticals, Inc.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 43,396,045 for, 1,086,059 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,612,255 | 3 | 6 | 0 | For |
| BlackRock | 2,942,277 | 0 | 0 | 0 | For |
| State Street | 2,202,609 | 0 | 0 | 0 | For |
| Fidelity | 1,606,123 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,158,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 858,121 | 0 | 0 | 0 | For |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 272,612 | 0 | 0 | 0 | For |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 124,191 | 0 | 0 | 0 | For |
| American Century | 0 | 121,737 | 0 | 0 | Against |
| Invesco | 0 | 111,394 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 91,876 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 83,229 | 0 | 0 | 0 | For |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,487 | 0 | 0 | 0 | For |
| Northwestern Mutual | 38,434 | 0 | 0 | 0 | For |
| Brighthouse | 35,420 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 17,554,726 for, 233,188 against, 3,921 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 4,562,559 | 0 | 0 | 0 | For |
| State Street | 3,359,876 | 1,936 | 0 | 0 | For |
| Lynx1 Capital Management LP | 2,959,109 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 2,704,900 | 0 | 0 | 0 | For |
| BlackRock | 2,233,167 | 134 | 0 | 0 | For |
| T. Rowe Price | 1,607,974 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 0 | 1,575,776 | 0 | Abstain |
| GEODE CAPITAL MANAGEMENT, LLC | 1,472,415 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,323,380 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 1,256,080 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 323,073 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 799,163 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 759,597 | 0 | 0 | 0 | For |
| Nuveen | 722,441 | 0 | 0 | 0 | For |
| DE Shaw | 629,582 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 589,198 | 0 | 0 | 0 | For |
| SCS Capital Management LLC | 553,152 | 0 | 0 | 0 | For |
| Vanguard | 487,497 | 0 | 0 | 0 | For |
| Charles Schwab | 479,980 | 0 | 0 | 0 | For |
| Northern Trust | 434,279 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 418,350 | 0 | 0 | Against |
| ArrowMark Colorado Holdings LLC | 403,544 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 236,470 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 226,310 | 0 | 0 | 0 | For |
| Tetragon Partners GP Ltd | 0 | 205,579 | 0 | 0 | Against |
Institutional-manager reports, all 203 managers: 30,919,283 for, 1,067,515 against, 1,576,681 abstained, 180 not voted, 693,118 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Prior year: 99.7% for (June 18, 2025 meeting) unchanged
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Agios Pharmaceuticals, Inc.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 48,511,213 for, 116,938 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,612,264 | 0 | 0 | 0 | For |
| BlackRock | 2,942,277 | 0 | 0 | 0 | For |
| State Street | 2,202,520 | 89 | 0 | 0 | For |
| Fidelity | 1,606,123 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,158,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 858,121 | 0 | 0 | 0 | For |
| TIAA | 707,224 | 0 | 0 | 0 | For |
| Charles Schwab | 479,723 | 0 | 0 | 0 | For |
| Dimensional | 353,624 | 0 | 0 | 0 | For |
| AMG FUNDS | 272,612 | 0 | 0 | 0 | For |
| First Trust | 150,541 | 0 | 0 | 0 | For |
| Equitable | 124,191 | 0 | 0 | 0 | For |
| American Century | 121,737 | 0 | 0 | 0 | For |
| Invesco | 111,394 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 91,876 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 86,352 | 0 | 0 | 0 | For |
| JPMorgan | 83,229 | 0 | 0 | 0 | For |
| ProShares | 55,683 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 47,229 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 45,441 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 43,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,487 | 0 | 0 | 0 | For |
| Northwestern Mutual | 38,434 | 0 | 0 | 0 | For |
| Brighthouse | 35,420 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 33,353 | 0 | 0 | 0 | For |
Fund voting reports, all 68 managers: 17,787,830 for, 89 against, 3,915 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,704,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,704,900 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,471,609 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.44% |
| 2 | BlackRock | 4.95% |
| 3 | State Street | 3.70% |
| 4 | Fidelity | 2.70% |
| 5 | Delaware/Macquarie | 1.95% |
| 6 | T. Rowe Price | 1.44% |
| 7 | TIAA | 1.19% |
| 8 | Charles Schwab | 0.81% |
| 9 | Dimensional | 0.59% |
| 10 | AMG FUNDS | 0.46% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.67% |
| 2 | State Street | 5.65% |
| 3 | Lynx1 Capital Management LP | 4.98% |
| 4 | Erste Asset Management GmbH | 4.55% |
| 5 | BlackRock | 3.76% |
| 6 | T. Rowe Price | 2.70% |
| 7 | BNP Paribas Asset Management Holding S.A. | 2.65% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.48% |
| 9 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 2.23% |
| 10 | Frazier Life Sciences Management, L.P. | 2.11% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Farallon Capital Management, L.L.C. | 5,917,400 | 9.95% | Schedule 13G, filed August 3, 2026 |
| BlackRock | 5,754,957 | 9.68% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 5,594,353 | 9.41% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,364,879 | 5.66% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 2,681,169 | 4.51% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 1,467,910 | 2.47% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 1,151,614 | 1.94% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 894,037 | 1.50% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 817,676 | 1.37% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 769,413 | 1.29% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 59,471,609 shares outstanding, as reported by Agios Pharmaceuticals, Inc. on its Form 10-Q dated April 24, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Agios Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 253 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,663 separate fund positions. On the most widely held item on that ballot — To vote, on an advisory basis, to approve the compensation paid to our named executive officers. — Agios Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Agios Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Agios Pharmaceuticals, Inc.’s 10-Q dated April 24, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Agios Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Agios Pharmaceuticals (AGIO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/agios-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.